Stock listing

LS Exchange:A2P4JE Protara Therapeutics, Inc. Aktie

German listing (LS Exchange) of Protara Therapeutics, Inc. · home listing NASDAQ:TARA

Follow Protara Therapeutics, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:TARA

$2.33 USD +0.01 (+0.4%)

Close on Oct 19, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:TARA

Since Jul 6, 2026 -42.9% · daily closes, Jul 6, 2026 – Oct 19, 2026, adjusted for splits
Day range
$2.30 – $2.43 USDOct 19, 2026
Volume
1.18M sharesOct 19, 2026
Market value
$137.7M USDAt the close on Oct 19, 2026 · price × 59.10M shares outstanding
Protara Therapeutics, Inc. logo
Ticker
LS Exchange:A2P4JE
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
LS Exchange
Currency
EUR

What changed lately

Calls

Replays

  • Protara Therapeutics (NASDAQ:TARA) Q1 2026 Earnings Call

    Tue, May 19, 2026 · 4:30 PM ET

    Watch Transcript

Latest news

Protara Therapeutics Completes Enrollment of the Phase 2b Open-Label Dose Confirmation Phase of the THRIVE-3 Registrational Trial of IV Choline Chloride in Patients on Parenteral Support

Oct 15, 2026

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Sep 8, 2026

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Aug 11, 2026

Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 20, 2026

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

May 18, 2026

Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC

May 15, 2026

Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

May 13, 2026

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting

Apr 27, 2026

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

Mar 10, 2026

TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Feb 23, 2026

All Protara Therapeutics, Inc. news

Decks

Protara Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 115 in all · newest Oct 15, 2026 · oldest 2020
Calls
1 call with a replay · 1 with a transcript · latest May 19, 2026
Decks
18 decks · latest August 2026

Where Protara Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:TARA · Home listingNASDAQUnited StatesUSD
LS Exchange:A2P4JE · This pageLS ExchangeGermanyEUR
gettex:1KPAgettexGermanyEUR
Lang & Schwarz:A2P4JELang & SchwarzGermanyEUR
BOATS:TARABOATSUnited StatesUSD
Tradegate:1KPATradegateGermanyEUR
Dusseldorf:1KPADusseldorfGermanyEUR
Frankfurt:1KPAFrankfurtGermanyEUR
Hamburg:1KPAHamburgGermanyEUR
Munich:1KPAMunichGermanyEUR
Stuttgart:1KPAStuttgartGermanyEUR

Log in to ask 6ix AI your own questions about Protara Therapeutics, Inc.